BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33372874)

  • 1. Aerosolized Liposomal Formulation Prevents Enhanced Drug Transfer from Fibrotic Lungs to the Systemic Circulation.
    Togami K; Kurasho K; Kanehira Y; Tada H; Chono S
    Curr Drug Deliv; 2021; 18(7):947-954. PubMed ID: 33372874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alteration in Intrapulmonary Pharmacokinetics of Aerosolized Model Compounds Due to Disruption of the Alveolar Epithelial Barriers Following Bleomycin-Induced Pulmonary Fibrosis in Rats.
    Togami K; Chono S; Tada H
    J Pharm Sci; 2016 Mar; 105(3):1327-34. PubMed ID: 26886341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis.
    Togami K; Kanehira Y; Yumita Y; Ozaki H; Wang R; Tada H; Chono S
    J Aerosol Med Pulm Drug Deliv; 2023 Dec; 36(6):289-299. PubMed ID: 37843890
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged distribution of aerosolized PEGylated liposomes in the lungs of mice with bleomycin-induced pulmonary fibrosis.
    Togami K; Maruta Y; Nanbu M; Tada H; Chono S
    Drug Dev Ind Pharm; 2020 Nov; 46(11):1873-1880. PubMed ID: 32940095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib-hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis.
    Togami K; Ogasawara A; Irie S; Iwata K; Yamaguchi K; Tada H; Chono S
    Eur J Pharm Biopharm; 2022 Mar; 172():203-212. PubMed ID: 35183716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-β
    Togami K; Yamaguchi K; Chono S; Tada H
    J Pharmacol Toxicol Methods; 2017 Jul; 86():19-27. PubMed ID: 28259823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2.
    Ivanova V; Garbuzenko OB; Reuhl KR; Reimer DC; Pozharov VP; Minko T
    Eur J Pharm Biopharm; 2013 Jun; 84(2):335-44. PubMed ID: 23228437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fyn-kinase and caveolin-1 in the alveolar epithelial junctional adherence complex contribute to the early stages of pulmonary fibrosis.
    Menzel V; Ziegler M; Hante N; Sake JA; Santos-Martinez MJ; Ehrhardt C; Kasper M; Barth K
    Eur J Pharm Sci; 2022 Aug; 175():106236. PubMed ID: 35710078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Intrapulmonary Pharmacokinetics and Drug Distribution Characteristics for the Treatment of Respiratory Diseases].
    Togami K
    Yakugaku Zasshi; 2020; 140(3):345-354. PubMed ID: 32115551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syndecan-2 exerts antifibrotic effects by promoting caveolin-1-mediated transforming growth factor-β receptor I internalization and inhibiting transforming growth factor-β1 signaling.
    Shi Y; Gochuico BR; Yu G; Tang X; Osorio JC; Fernandez IE; Risquez CF; Patel AS; Shi Y; Wathelet MG; Goodwin AJ; Haspel JA; Ryter SW; Billings EM; Kaminski N; Morse D; Rosas IO
    Am J Respir Crit Care Med; 2013 Oct; 188(7):831-41. PubMed ID: 23924348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleomycin Induces Drug Efflux in Lungs. A Pitfall for Pharmacological Studies of Pulmonary Fibrosis.
    Park JK; Coffey NJ; Bodine SP; Zawatsky CN; Jay L; Gahl WA; Kunos G; Gochuico BR; Malicdan MCV; Cinar R
    Am J Respir Cell Mol Biol; 2020 Feb; 62(2):178-190. PubMed ID: 31419911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic administration of inhaled INS1009, a treprostinil prodrug formulation, inhibits bleomycin-induced pulmonary fibrosis in rats.
    Corboz MR; Zhang J; LaSala D; DiPetrillo K; Li Z; Malinin V; Brower J; Kuehl PJ; Barrett TE; Perkins WR; Chapman RW
    Pulm Pharmacol Ther; 2018 Apr; 49():95-103. PubMed ID: 29408757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.
    Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E
    Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alveolar epithelial TET2 is not involved in the development of bleomycin-induced pulmonary fibrosis.
    Qin W; Crestani B; Spek CA; Scicluna BP; van der Poll T; Duitman J
    FASEB J; 2021 May; 35(5):e21599. PubMed ID: 33913570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway.
    Saito S; Zhuang Y; Shan B; Danchuk S; Luo F; Korfei M; Guenther A; Lasky JA
    PLoS One; 2017; 12(10):e0186615. PubMed ID: 29045477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation Lenalidomide-Loaded Liposome for Bleomycin-Induced Pulmonary Fibrosis Improvement.
    Luo Z; Ji L; Liu H; Sun Y; Zhao C; Xu X; Gu X; Ai X; Yang C
    AAPS PharmSciTech; 2023 Nov; 24(8):235. PubMed ID: 37973629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis.
    Senoo T; Hattori N; Tanimoto T; Furonaka M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Yokoyama A; Kohno N
    Thorax; 2010 Apr; 65(4):334-40. PubMed ID: 20388759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent, Progressive Pulmonary Fibrosis and Epithelial Remodeling in Mice.
    Redente EF; Black BP; Backos DS; Bahadur AN; Humphries SM; Lynch DA; Tuder RM; Zemans RL; Riches DWH
    Am J Respir Cell Mol Biol; 2021 Jun; 64(6):669-676. PubMed ID: 33406369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation.
    Chen YL; Zhang X; Bai J; Gai L; Ye XL; Zhang L; Xu Q; Zhang YX; Xu L; Li HP; Ding X
    Cell Death Dis; 2013 Jun; 4(6):e665. PubMed ID: 23764846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-fibrotic effect of inhibition of TGFβ-ALK5 signalling in experimental pulmonary fibrosis in mice is attenuated in the presence of concurrent γ-herpesvirus infection.
    Smoktunowicz N; Alexander RE; Franklin L; Williams AE; Holman B; Mercer PF; Jarai G; Scotton CJ; Chambers RC
    Dis Model Mech; 2015 Sep; 8(9):1129-39. PubMed ID: 26138704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.